With the advantages of multispecific antibodies, the ImmuBridge™ platform is paving the way for precision medicine in oncology and immunotherapy. Leveraging next-generation TCEs, we are redefining the battle against cancer, targeting malignant cells with unprecedented accuracy and efficacy. Partner with us to shape the future of oncology and immunotherapy.
Multispecific antibodies, a revolutionary class of engineered antibodies, are designed to target multiple antigens simultaneously. By combining different antigen-binding sites in a single molecule, they offer a unique approach to cancer therapeutic interventions.
Enhanced Targeting Specificity
Multispecific antibodies enhance specificity towards cancer cells while sparing healthy tissues by binding to distinct targets on tumor cells. This helps minimize off-target effects and reduce the risk of adverse reactions.
Synergistic Immune Activation
The multiple antigen-binding sites of these antibodies can also engage immune cells, such as T cells, participating in multiple pathways within the immune system, stimulating potent immune responses against cancer.
Overcoming Tumor Heterogeneity
Multispecific antibodies target broader spectrum of tumor cell populations by binding to multiple antigens on their surface, overcoming tumor heterogeneity, reducing escape chances, and enhancing therapeutic efficacy.
Versatility in Therapeutic Design
Multispecific antibodies can be precisely designed to suit specific therapeutic targets. By customizing the binding specificity, valency, and effector functions of these antibodies, their efficacy can be optimized.
Multispecific antibodies are not limited to directly targeting tumor cells. They can also be engineered to modulate immune checkpoint pathways, enhance antibody-dependent cellular cytotoxicity (ADCC), or deliver cytotoxic payloads directly to cancer cells. Such multifaceted mechanisms of action make multispecific antibodies a promising tool for personalized cancer therapy and overcoming therapeutic resistance.
Focusing on innovative off-the-shelf immunotherapies, our company has developed the ImmuBridge™ multispecific antibody platform. Utilizing this platform, the design and development of next-generation T-cell engagers (TCEs) with multiple antigen-binding sites offer an effective approach to harnessing the immune system against cancer. These engineered molecules can elicit potent immune responses, orchestrating precise and targeted cytotoxicity towards cancer cells within the intricate milieu of the tumor microenvironment.
Fig. 1 Structure of the trispecific T cell engagers (TCEs). TA: Target antigen; CD3: Part of the T-cell receptor (TCR) complex; 2nd signal: The binding site can be designed to target common surface proteins of T cells or tumor cells.
IgG-like Antibody Structure
IgG-like structure design ensures stability, pharmacokinetic properties, and effector functions similar to IgG antibodies, enhancing the therapeutic potential and clinical applicability of multispecific antibodies.
Versatile Target Antigen (TA) Design
TA allows for the targeting of the same or different epitopes on a single antigen or the simultaneous targeting of two distinct antigens. This flexibility enables tailored approaches for various cancers.
High Tumor Targeting and Safety
The advanced design of multispecific antibodies offers high tumor-targeting specificity, minimizing off-target effects and reducing the risk of adverse reactions, thereby enhancing therapeutic efficacy and safety.
Potent Immune Response
Our next-generation TCE enhances cytotoxic mechanisms and tumor cell destruction by simultaneously activating multiple molecular targets on the surface of T cells, thereby improving anti-tumor efficacy.
Excellent Drug Developability
Our platform facilitates the development of multispecific antibodies with different combinations of targets. This versatility enables the customization for various cancer therapies, expanding the application of the platform.
ImmuBridge™ represents a promising advancement in the fields of oncology and immunotherapy, with significant potential to enhance the precision, efficacy, and durability of cancer immunotherapy.
The bispecific T cell engagers (BiTEs) provide a precise mechanism for the engagement of T cells with tumor cells. By directing the immune response against tumor antigens, BiTE antibodies significantly enhance tumor targeting compared to traditional monoclonal antibodies, reducing off-target effects.
Trispecific Antibody Development
Trispecific antibodies can potentiate immune responses against cancer cells by engaging multiple target proteins on T cell surfaces. This robust immunological mechanism holds promise for yielding improved therapeutic outcomes in individuals with advanced or refractory malignancies.
The ImmuBridge™ platform excels beyond the realm of BiTE and trispecific antibodies. Its versatility allows for the tailored design of antibodies targeting diverse combinations of antigens, adept at addressing the intricate landscape of cancer therapeutics. More applications await your exploration.
Professional and
Experienced Team
Cutting Edge Technology
Platform
Market Adaptability and
Agility
Excellent and
Outstanding Partner
We are actively seeking collaboration opportunities to license our multispecific antibody platform or co-develop multispecific antibody drug candidates. If you are interested in our platform, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Our ImmuBridge™️ platform is specifically designed for developing multispecific antibodies targeting tumor antigens. We provide comprehensive research services for cancer immunotherapy to drive advancements in the field.
